Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC

• Published in: Clinics and research in hepatology and gastroenterology 2023-10, Vol.47 (8), p.102199, Article 102199
• Main Authors: Chaibi, Sayma, Larrey, Edouard, Couty, Jean Pierre, Sultanik, Philippe, Campani, Claudia, Blaise, Lorraine, Wagner, Mathilde, Desdouets, Chantal, Nault, Jean Charles, Thabut, Dominique, Allaire, Manon
• Format: Article
• Language: English
• Subjects: Albumin; Atezolizumab-Bevacizumab; Hepatocellular carcinoma; Overall survival; prognostic factors
• ISSN: 2210-7401; 2210-741X; 2210-741X
• DOI: 10.1016/j.clinre.2023.102199

•Albumine infusion during Atezolizumab-Bevacizumab in Child-Pugh B patients reduce expansion/development of ascites•Albumine infusion during Atezolizumab-Bevacizumab in Child-Pugh B patients do not improve overall survival•Similar rate of hepatic encephatolopathy and acute variceal bleeding were observed in Child-Pugh B patients who received or not albumin infusion in combination with Atezolizumab-Bevacizumab Long-term albumin infusions have been associated with improved outcomes in decompensated cirrhotic patients. This study aimed to evaluate the impact of albumin infusion on the prognosis of Child-Pugh B patients undergoing treatment with AtezoBev for advanced hepatocellular carcinoma (HCC). We conducted a retrospective multicentric study that included all Child-Pugh B cirrhotic patients treated with AtezoBev since 2020. We examined the effects of albumin infusion (40 g every 3 weeks) on overall survival (OS) and the occurrence of cirrhosis-related complications. Time-to-event data were analyzed using Kaplan-Meier with the log-rank test and Cox models. Forty-seven HCC patients with a Child-Pugh B score who received AtezoBev were included, of whom 26% also received albumin infusions every 3 weeks. The two groups were similar in terms of liver function and HCC parameters. The median OS was 4.4 and 5.8 months (p = 0.42) for patients who did or did not receive albumin, respectively. The occurrence of hepatic encephalopathy and variceal bleeding was similar between the two groups. However, albumin infusions were associated with a significantly lower rate of ascites expansion/development (13% versus 57%, p = 0.005). Cox analysis revealed that a history of ascites (HR=3.82 [95% CI: 1.73–8.48]) was independently associated with a higher risk of ascites expansion/development, whereas albumin infusions were protective (HR=0.07 [95% CI: 0.01–0.54]). Albumin infusion did not improve overall survival in Child-Pugh B HCC patients treated with AtezoBev, but it significantly reduced the expansion/development of ascites.